SS-31 — Safety, Research, Risks & Legal Status

Not medical advice. SS-31 is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	Szeto-Schiller 31, elamipretide, MTP-131
Category	Peptide
cardiolipin	Unique phospholipid found in inner mitochondrial membrane; essential for electron transport chain function
triphenylphosphonium	Chemical moiety that enables accumulation in mitochondria due to mitochondrial membrane potential
US legal status	Research chemical; not FDA-approved for general use; clinical trial phase (Reata Pharmaceuticals); sold as research chemical outside trials in US

What is SS-31?

4-amino acid peptide that targets inner mitochondrial membrane; studied to reduce mitochondrial dysfunction and oxidative stress. SS-31 is a targeted mitochondrial antioxidant that may preserve mitochondrial membrane potential and protect cardiolipin from oxidative damage in specific disease states.

How it works

SS-31 is a mitochondria-targeted peptide that accumulates in the inner membrane due to a triphenylphosphonium (TPP) moiety. It scavenges reactive oxygen species (ROS) and prevents cardiolipin oxidation, stabilizing electron transport chain proteins and preserving ATP production under oxidative stress.

Background & history

SS-31 was discovered and developed at Washington University School of Medicine by David Mochly-Rosen and colleagues in the 1990s-2000s. Initial focus was cardioprotection in acute myocardial infarction and ischemia-reperfusion injury. Reata Pharmaceuticals acquired development rights and advanced the compound into clinical trials for rare mitochondrial diseases and cardiac indications.

What the research says

Preclinical and Phase 2 human trials in specific diseases (barth syndrome, cardiology); general anti-aging claims lack robust human data; mitochondrial targeting is real but clinical benefit unproven in healthy subjects. Published trials in Barth syndrome and acute kidney injury show modest benefit; extrapolation to healthy aging is not evidence-based.

Reported effects

Reported to reduce cardiolipin oxidation in mitochondria
Studied to preserve mitochondrial membrane potential in stressed cells
Animal models suggest protection against ischemic injury and metabolic dysfunction
May support endothelial function and reduce oxidative stress
Preclinical work suggests potential cardioprotection in heart failure models

Dosing & administration (informational)

Human trials have used intravenous or subcutaneous doses ranging 0.5-2.0 mg/day, typically given daily or 3x weekly over weeks to months in disease populations. Animal studies at 0.03-0.3 mg/kg showed mitochondrial effects. No established human dosing for healthy subjects; pharmacokinetics in non-disease states unknown.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

Generally well-tolerated in early human trials; injection site reactions noted
Long-term safety in healthy humans unknown; trials focused on disease states
Synth must be GMP and high-purity; impurities can compromise mitochondrial bio-availability
Injection route required; proper sterile handling and cold chain essential
Pregnancy/nursing: no data; avoid. Kidney disease: limited data; use caution
Photosensitivity potential unclear; sun exposure during research use not well-characterized

Drug & supplement interactions

No known major drug interactions documented; not well-studied in combination
Potential interaction with other mitochondrial agents (CoQ10, ubiquinone) not characterized
Antioxidant combinations (vitamin E, NAC) may have redundant effect; safety unknown
Beta-blockers and ACE inhibitors (cardiac drugs) overlap in mechanisms; interactions not tested

Who should avoid it

Severe liver or kidney disease (metabolism and clearance unknown)
Pregnancy and nursing (no safety data)
Active heart arrhythmia or severe cardiac instability (may affect electrolyte balance)
Photosensitizing drugs if photosensitivity is a concern (data limited)
Concurrent enrollment in other mitochondrial-targeting drug trials

How it is commonly combined

Theoretically, SS-31 could be combined with other mitochondrial supports (ubiquinone, pyrroloquinoline quinone) or antioxidants (alpha-lipoic acid, NAC), but no studies validate safety or synergy. Off-label stacking in wellness circles is anecdotal only.

Legal & regulatory. Research chemical; not FDA-approved for general use; clinical trial phase (Reata Pharmaceuticals); sold as research chemical outside trials in US

Quality & harm reduction

T
h
i
r
d
-
p
a
r
t
y
C
O
A
w
i
t
h
i
d
e
n
t
i
t
y
a
n
d
p
u
r
i
t
y
(
H
P
L
C
9
8
%
+
)
.
L
C
-
M
S
o
r
a
m
i
n
o
a
c
i
d
a
n
a
l
y
s
i
s
f
o
r
s
e
q
u
e
n
c
e
c
o
n
f
i
r
m
a
t
i
o
n
.
E
n
d
o
t
o
x
i
n
t
e
s
t
i
n
g
l
e
s
s
t
h
a
n
0
.
2
5
I
U
/
k
g
.
S
t
e
r
i
l
e
,
s
i
n
g
l
e
-
u
s
e
v
i
a
l
s
;
f
r
e
e
z
e
-
2
0
°
C
o
r
r
e
f
r
i
g
e
r
a
t
e
2
-
8
°
C
;
c
o
l
d
c
h
a
i
n
m
a
i
n
t
a
i
n
e
d
t
h
r
o
u
g
h
o
u
t
.

Safer, legal alternative we recommend

High-intensity interval training and antioxidant-rich foods. Exercise naturally improves mitochondrial density and function; berries, nuts, and leafy greens provide polyphenols and do not carry research-chemical injection risk.

See our recommended pick

Lab testing & harm-reduction tools

If you are going to research a compound, verifying identity and purity is the single most protective step. Independent analytical testing and sterile-handling supplies reduce risk.

Compare testing options

Frequently asked questions

Does SS-31 slow aging?

Animal models show anti-oxidant effects, but human data in healthy aging is missing. Marketed anti-aging claims are preliminary.

What diseases has SS-31 been studied in?

Barth syndrome, heart failure, acute kidney injury, and rare mitochondrial disorders. Not FDA-approved; development ongoing at Reata Pharmaceuticals.

Is it safe for long-term use?

Unknown. Phase 2 trials were short-term; no long-term human safety data exists outside clinical trials.

Can I use it for athletic performance?

No robust data; not studied in sports. Theoretical mitochondrial support does not equal proven ergogenic benefit.

Why is it called a targeting peptide?

The triphenylphosphonium tail allows SS-31 to accumulate specifically in mitochondria, unlike non-targeted antioxidants.

References & further reading

Mitochondrial-targeted antioxidants and cardioprotection: Antioxidants and Redox Signaling journal
SS-31 and elamipretide clinical trials: Journal of the American College of Cardiology and specialized cardiomyopathy journals
Cardiolipin oxidation and mitochondrial dysfunction: Biochemistry and bioenergetics literature
Targeted peptide drug delivery: Pharmaceutical Research and Journal of Controlled Release
Barth syndrome and mitochondrial dysfunction: rare disease and metabolic medicine journals